Studies have confirmed that blocking PD-1/PD-L1 activates and upregulates the expression of CD8+ T-cells, increases their tumor-killing activity, and induces the expression of major histocompatibility complex molecules on the surface of cancer cells, exposing more cancer cells to immune cells (108). The gene discussed is PDCD1; the disease is neoplasm.